We conclude that TRPV1 antagonists may represent a class of novel anti-diabetic drugs that regulate hyperglycemia and prevent weight gain by ameliorating the low-grade inflammation that is seen in diabetes and in obesity. Here, TRPV1 is linked to obesity due to melanocortin 4 receptor deficiency.